Amorphous solid dispersion of fruquintinib

Amorphous solid dispersions of Fruquintinib with carriers like co-povidone and Eudragit address stability and solubility issues, enhancing bioavailability and suitability for treating cancer and other angiogenesis-related disorders.

WO2024231952A1PCT designated stage expired Publication Date: 2024-11-14DR REDDYS LAB LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2024/050494
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-07
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for improving the dissolution characteristics and bioavailability of Fruquintinib, such as particle size reduction and solid dispersions, face limitations in physical stability and solubility, particularly in the small intestine tract, leading to low bioavailability.

Method used

Development of amorphous solid dispersions of Fruquintinib with pharmaceutically acceptable carriers like co-povidone, HPMC, and Eudragit, prepared through solvent-based processes followed by solvent removal techniques like spray drying, to enhance solubility, stability, and bioavailability.

Benefits of technology

The amorphous solid dispersions exhibit improved stability, solubility, and bioavailability, making them suitable for large-scale preparation and effective pharmaceutical compositions for treating angiogenesis-related disorders like cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000012_0002
    Figure IMGF000012_0002
Patent Text Reader

Abstract

The present application provides an amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carriers and processes for the preparation thereof. The present application specifically provides an amorphous solid dispersion of Fruquintinib with a pharmaceutically acceptable carrier, selected from a group of co-povidone, HPMC, HPMC-AS, Eudragit, HPC and mixtures thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] AMORPHOUS SOLID DISPERSION OF FRUQUINTINIB

[0002] CROSS REFERENCE

[0003] This application claims the priority of our Indian provisional application 202341032721 filed on 09thMay 2023.

[0004] FIELD OF INVENTION

[0005] The present application relates to amorphous solid dispersion of Fruquintinib and pharmaceutical composition thereof.

[0006] BACKGROUND OF THE INVENTION

[0007] The drug compound having the adopted name “Fruquintinib” has chemical name: 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-l- benzofuran-3 -carboxamide of formula (I) as below

[0008] Formula (I)

[0009] Fruquintinib is an inhibitor of vascular endothelial growth factor receptors (VEGFRs), developed and marketed by HutchMed MediPharma Limited as Elunate® oral capsules for the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies.

[0010] US 7829574 B2 patent first discloses Fruquintinib or the pharmaceutically acceptable salt generically and specifically and its use thereof for the treatment of angiogenesis-related disorder (e.g., cancer, age-related macular degeneration, or chronic inflammatory disease).

[0011] Subsequently, the US 10519142 B2 patent describes crystalline forms of Fruquintinib (Form I, Form III and Form VII). The US’ 142 patent also describes the solvated forms of Fruquintinib, namely, Form II (EtOH), Form IV (AcOH) and Form VIII (dioxane).

[0012] Several methods to improve the dissolution characteristics of active pharmaceutical ingredient (API) compounds have been reported, including particle size reduction, formation of solvates, complexes and micro spheres. Additionally, attempts have been made to improve bio-availability provided by solid dosage forms by forming solid dispersions of drugs. Solid dispersions create a mixture of a poorly water-soluble drug and highly soluble carriers. Solid dispersions may increase bioavailability by decreasing the energy required for solubilizing the drug and increasing the stability of the drug in solution. Traditionally these methods carry inherent limitations concerning physical stability of the solid dispersion on storage, problems with grinding or difficulty of removal of the solvent. Furthermore, it is important that the drug released from the solid phase does not precipitate in the small intestine tract but remains water- soluble in the aqueous fluids of the small intestine tract, since such precipitation results in low bioavailability.

[0013] Therefore, there remains a need for alternate solid forms of Fruquintinib such as amorphous solid dispersions and preparative processes thereof, exhibiting desired properties such as solubility, bioavailability and stability. Inventors of the present application have developed amorphous solid dispersions of Fruquintinib which are not only pure, stable, reproducible and amicable for large scale preparation, but also suitable for preparation of a pharmaceutical composition.

[0014] SUMMARY OF THE INVENTION

[0015] One aspect of the present application relates to amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carrier and processes for preparation thereof.

[0016] Another aspect of the present application relates to a pharmaceutical composition comprising amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carrier.

[0017] Yet another aspect of the present application relates to use of amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carrier for the treatment of diseases associated with KDR inhibition, for example angiogenesis-related disorders, such as, cancer, age-related macular degeneration and chronic inflammatory diseases.

[0018] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods, and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0019] BRIEF DESCRIPTION OF THE DRAWING

[0020] Figure 1 is an illustrative Powder X-Ray Diffraction (hereinafter referred as “PXRD”) of amorphous solid dispersion of Fruquintinib with co-povidone (1 :9, w / w).

[0021] Figure 2 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with co-povidone (1 :4, w / w).

[0022] Figure 3 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with Eudragit LI 00 (1:4, w / w).

[0023] Figure 4 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with HPMC (1:4, w / w). Figure 5 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with HPMC-AS (1 :4, w / w).

[0024] Figure 6 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with Eudragit L-100 and HPC (1 :2:2, w / w).

[0025] Figure 7 is an illustrative PXRD of amorphous solid dispersion of Fruquintinib with HPC (1 :4, w / w).

[0026] DETAILED DESCRIPTION OF THE INVENTION

[0027] As used herein, "comprising" means the elements recited, or their equivalent in structure or function, plus any other element or elements which are not recited. The terms "having" and "including" are also to be construed as open ended unless the context suggests otherwise.

[0028] All ranges recited herein include the endpoints, including those that recite a range "between" two values.

[0029] Terms such as "about," "generally," "substantially," and the like are to be construed as modifying a term or value such that it is not an absolute, but does not read on the prior art. Such terms will be defined by the circumstances and the terms that they modify as those terms are understood by those of skill in the art. This includes, at very least, the degree of expected experimental error, technique error and instrument error for a given technique used to measure a value.

[0030] The term "about" when used in the present application preceding a number and referring to it, is meant to designate any value which lies within the range of ±10%, specifically within a range of ±5%, more specifically within a range of ±2%, still more specifically within a range of ±1 % of its value. For example, "about 10" should be construed as meaning within the range of 9 to 11, specifically within the range of 9.5 to 10.5, more specifically within the range of 9.8 to 10.2, and still more specifically within the range of 9.9 to 10.1. One aspect of the present application provides amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carriers.

[0031] In embodiments, the pharmaceutically acceptable carrier may be any suitable carrier known in the art. Specifically, the pharmaceutically acceptable carrier may include but not limited to selected from the group consisting of vinylpyrrolidone-vinyl acetate copolymer (co-povidone); polyvinyl pyrrolidone (PVP); polymethacrylate-based copolymers; polyvinylcaprolactam-based copolymers; cyclodextrins; chitosan; polyvinyl alcohol; alginic acid; hydroxypropyl methylcellulose (also referred as HPMC or hypromellose) such as HPMC E3; hydroxypropyl methylcellulose acetate succinate (also referred as HPMC-AS or hypromellose acetate succinate) such as L, M, and H grades of HPMC-AS; Eudragit; hydroxypropyl cellulose (Also referred as HPC); methylcellulose (also referred as MC); hypromellose phthalate (also referred as HPMC-P); cellulose acetate phthalate; silicon dioxide; polysaccharides; heteropolysaccharides (pectins); poloxamers; poloxamines; ethylene vinyl acetates; polyethylene glycols; propylene glycols; polyvinylacetates; phosphatidylcholines (lecithins); miglyols; polylactic acid; polyhydroxybutyric acid; neucilin, dextrans or mixture thereof.

[0032] In embodiments, the ratio between Fruquintinib and the pharmaceutically acceptable carrier may range from about 1 :0.1 to about 1 : 15 by weight. Specifically, the ratio of Fruquintinib and pharmaceutically acceptable carrier may range from about 1 : 1 to about 1 : 12. More specifically, the ratio of Fruquintinib and pharmaceutically acceptable carrier may range from about 1 :3 to about 1 : 10.

[0033] In a specific embodiment, the pharmaceutically acceptable carrier may be selected from a group of co-povidone, HPMC, HPMC-AS, HPC, Eudragit and mixture thereof. One specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with co-povidone. Another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with copovidone in a ratio of 1 :9 w / w. Yet another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with copovidone in a ratio of 1 :4 w / w.

[0034] Still another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with HPMC. Yet another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with HPMC in a ratio of 1 :4 w / w.

[0035] Yet another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with HPMC-AS. Another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with HPMC in a ratio of 1 :4 w / w.

[0036] Another specific embodiment of the present application provides amorphous solid dispersion of Fruquintinib with Eudragit. Another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with Eudragit in a ratio of 1 :4 w / w.

[0037] Still another specific embodiment of the present application provides amorphous solid dispersion of Fruquintinib with HPC. Another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with HPC in a ratio of 1 :4 w / w.

[0038] Yet another specific embodiment of the present application provides amorphous solid dispersion of Fruquintinib with a mixture of Eudragit and HPC. Another specific aspect of the present application provides amorphous solid dispersion of Fruquintinib with Eudragit and HPC in a ratio of 1 :2:2 w / w.

[0039] Another aspect of the present application provides a process for the preparation of amorphous solid dispersion of Fruquintinib and one or more pharmaceutically acceptable carriers, comprising the steps of providing a solution of Fruquintinib and pharmaceutically acceptable carrier in a solvent and removing of the solvent.

[0040] In embodiments, solvent may be selected from the group consisting of methanol, ethanol, 1 -propanol, 2-propanol, 1 -butanol, 2-butanol, 1 -pentanol, 2- pentanol, 3 -pentanol, tetrahydrofuran, 1,4-di oxane, acetone, methyl ethyl ketone, methyl isobutyl ketone; methyl acetate, ethyl acetate, isopropyl acetate, acetonitrile, dimethylformamide, dimethylsulfoxide, dimethylacetamide, N- methylpyrrolidone, dichloromethane, water or mixtures thereof. Specifically, the solvent is a mixture of methanol and acetone or mixture of methanol and tetrahydrofuran.

[0041] In embodiments, a solution of Fruquintinib and pharmaceutically acceptable carrier may be prepared at any suitable temperatures, such as about 0°C to about the reflux temperature of the solvent used. Stirring and heating may be used to reduce the time required for the dissolution process.

[0042] In embodiments, a solution of Fruquintinib and pharmaceutically acceptable carrier may be filtered to make the solution free of unwanted particles.

[0043] In embodiments, the obtained solution may be optionally treated with an adsorbent material, such as carbon and / or hydrose, to remove colored components, etc., before filtration.

[0044] In an embodiment, removal of solvent may be carried out by methods known in the art or any procedure disclosed in the present application. In specific embodiments, removal of solvent may include, but not limited to: solvent evaporation under atmospheric pressure or reduced pressure / vacuum such as a rotational distillation using Buchi Rotavapor, spray drying, freeze drying, thin film drying, agitated thin film drying, rotary vacuum paddle dryer (RVPD) and the like.

[0045] In embodiments, removal of solvent may be carried out by spray drying with inlet temperature 70°C, outlet temp 40°C & flow rate about 4 g / min to about 8 g / min.

[0046] Another aspect of the present application provides pharmaceutical composition comprising amorphous solid dispersion of Fruquintinib and one or more pharmaceutically acceptable excipients. Amorphous solid dispersion of Fruquintinib together with one or more pharmaceutically acceptable excipients of the present application may be formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as, but not limited to, syrups, suspensions, dispersions, and emulsions; and injectable preparations such as, but not limited to, solutions, dispersions, and freeze dried compositions. Formulations may be in the forms of immediate release, delayed release, or modified release. Further, immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems. The compositions may be prepared using any one or more of techniques such as direct blending, dry granulation, wet granulation, and extrusion and spheronization. Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated, and modified release coated.

[0047] It was found that amorphous solid dispersion of Fruquintinib of the present application is stable and has good physico-chemical properties. The amorphous solid dispersion of the present application may be easily formulated into a pharmaceutical composition comprising Fruquintinib along with one or more pharmaceutically acceptable excipients.

[0048] Yet another aspect of the present application relates to use of amorphous solid dispersion of Fruquintinib for the treatment of diseases associated with KDR inhibition, specifically cancer. One specific aspect of the present application relates to use of amorphous solid dispersion of Fruquintinib for the treatment of metastatic colorectal cancer (mCRC).

[0049] Another embodiment of the present application provides use of the amorphous solid dispersion of Fruquintinib with pharmaceutically acceptable carrier for the manufacture of a medicament for treatment and / or prevention of metastatic colorectal cancer (mCRC).

[0050] XRD method of analysis:

[0051] All PXRD data reported herein are obtained using a PANalytical X-ray Diffractometer and Bruker D8 advance X-ray Diffractometer with copper Ka radiation.

[0052] HPLC method of analysis for purity:

[0053] Column: YMC Triat C 18 150 * 4.6 mm, 3.0 mm; Wavelength: 238 nm; Column temperature: 30°C; Injection volume: 5 mL; Elution: Gradient; Diluent: Acetonitrile: water (500:500) v / v; Needle wash: Acetonitrile: water (800:200) v / v Buffer Preparation: Dissolve 1.36 g of potassium dihydrogen phosphate into 1000 ml of MQ water and adjust pH to 7.50 with dilute KOH solution.

[0054] Mobile Phase-A: Mix buffer and acetonitrile in the ratio of 900: 100 v / v and degassed.

[0055] Mobile Phase-B: Mix acetonitrile and Milli Q water in the ratio of 800:200 v / v and degassed.

[0056] Starting material may be either in a crystalline or amorphous state Fruquintinib or any other form known in the literature.

[0057] Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Variations of the described procedures, as will be apparent to those skilled in the art, are intended to be within the scope of the present application.

[0058] EXAMPLES

[0059] Example-1: Process for the preparation of amorphous solid dispersion of Fruquintinib with copovidone (1:9, w / w)

[0060] Fruquintinib (200 mg) and copovidone (1800 mg) were dissolved in a mixture of methanol (60 mL) and acetone (80 ml) at 55°C. The solution was filtered to make particle free. The obtained clear solution was spray dried to obtain amorphous solid dispersion of Fruquintinib with copovidone.

[0061] PXRD diagram: Illustrated in Figure- 1.

[0062] Example-2: Process for the preparation of amorphous solid dispersion of Fruquintinib with copovidone (1:9, w / w)

[0063] Fruquintinib (200 mg) and copovidone (1800 mg) were dissolved in a mixture of methanol and tetrahydrofuran (100 mL) at 55°C. The solution was filtered to make particle free. The obtained clear solution was spray dried to obtain amorphous solid dispersion of Fruquintinib with copovidone.

[0064] Example-3: Process for the preparation of amorphous solid dispersion of Fruquintinib with copovidone (1:9, w / w)

[0065] Fruquintinib (1 g) and copovidone (9 g) were dissolved in a mixture of methanol (100 mL) and acetone (200 ml) at 55°C. The solution was filtered to make particle free. The obtained clear solution was spray dried to obtain amorphous solid dispersion of Fruquintinib with copovidone.

[0066] Glass Transition Temperature: 102.96 °C

[0067] Example-3a: Stability of amorphous solid dispersion of Fruquintinib with copovidone (1:9, w / w)

[0068] The amorphous solid dispersion of Fruquintinib with copovidone (1 :9, w / w), as prepared in example 3, was kept at 25°C / 60% RH and 40°C / 75% RH in closed condition and found to be stable, both physically and chemically, after one month.

[0069] Example-4: Process for the preparation of amorphous solid dispersion of Fruquintinib with copovidone (1:4, w / w)

[0070] Fruquintinib (2.5 g) was added to a mixture of methanol and acetone (900 ml, 1 :2) followed by THF (30 ml) and then mixture of dimethylsulfoxide (DMSO)- dimethylformamide (DMF) solution (10 ml, 1 : 1) at 60°C and stirred for 2 hrs to get clear solution. Co-povidone (10 gms) and methanol (60 ml) was added to the above solution and then stirred for 15 min. The solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0071] PXRD: Illustrated in Figure-2.

[0072] Glass Transition Temperature: 89.9 °C

[0073] Example-4a: Stability of amorphous solid dispersion of Fruquintinib with copovidone (1:4, w / w)

[0074] The amorphous solid dispersion of Fruquintinib with copovidone (1 :4), as prepared in example 4, was kept at 25°C / 60% RH for one week in open condition and found to be stable.

[0075] Example-5: Process for the preparation of amorphous solid dispersion of Fruquintinib with Eudragit L-100 (1:4, w / w)

[0076] Fruquintinib (2.5 g) was added to a mixture of THF and methanol (400 ml, 4: 1) at 60°C and stirred for 20 min to get clear solution. Eudragit LI 00 (10 gms) and methanol (400 ml) was added to the above solution and then stirred for 15 min. The obtained solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0077] PXRD: Illustrated in Figure-3.

[0078] Glass Transition Temperature: 99.5 °C

[0079] Example-5a: Stability of amorphous solid dispersion of Fruquintinib with Eudragit L-100 (1:4)

[0080] Amorphous solid dispersion of Fruquintinib with Eudragit L-100 (1 :4), as prepared in example 5, was kept at 80% RH, 25°C / 60% RH and 40°C / 75% RH for one week in open condition and found to be chemically and physically stable.

[0081] The amorphous solid dispersion of Fruquintinib with Eudragit L-100 (1 :4), as prepared in example 5, was also kept at 25°C / 60% RH and 40°C / 75% RH for one month in closed condition and found to be chemically and physically stable.

[0082] Example-6: Process for the preparation of amorphous solid dispersion of Fruquintinib with HPMC (1:4, w / w)

[0083] Fruquintinib (2.5 g) was added to a mixture of THF and methanol (400 ml, 4: 1) at 60°C and stirred for 20 min to get clear solution. HPMC (10 gms) and methanol (400 ml) was added to the above solution and then stirred for 15 min. The obtained solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0084] PXRD: Illustrated in Figure-4.

[0085] Glass Transition Temperature: 111.2 °C

[0086] Example-6a: Stability of amorphous solid dispersion of Fruquintinib with HPMC (1:4, w / w)

[0087] Amorphous solid dispersion of Fruquintinib with HPMC (1 :4), as prepared in example 6, was kept at 80% RH, 25°C / 60% RH and 40°C / 75% RH for one week in open condition and found to be physically and chemically stable.

[0088] The amorphous solid dispersion of Fruquintinib with HPMC (1 :4), as prepared in example 6, was also kept at 25°C / 60% RH and 40°C / 75% RH for one month in closed condition and found to be physically and chemically stable.

[0089] Example-7: Process for the preparation of amorphous solid dispersion of Fruquintinib with HPMC-AS (1:4, w / w)

[0090] Fruquintinib (2.5 g) was added to a mixture of THF and methanol (400 ml, 4: 1) at 60°C and stirred for 20 min to get clear solution. HPMC AS (10 gms) and methanol (400 ml) was added to the above solution and then stirred for 15 min. The obtained solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0091] PXRD: Illustrated in Figure-5.

[0092] Glass Transition Temperature: 119.6 °C

[0093] Example-7a: Stability of amorphous solid dispersion of Fruquintinib with HPMC-AS (1:4, w / w)

[0094] The amorphous solid dispersion of Fruquintinib with HPMC-AS (1 :4, w / w), as prepared in example 7, was kept at 80% RH, 25°C / 60% RH and 40°C / 75% RH for one week in open condition and found to be physically and chemically stable.

[0095] The amorphous solid dispersion of Fruquintinib with HPMC-AS (1 :4, w / w), as prepared in example 7, was also kept at 25°C / 60% RH and 40°C / 75% RH for one month in closed condition and found to be physically and chemically stable.

[0096] Example-8: Process for the preparation of amorphous solid dispersion of

[0097] Fruquintinib with Eudragit L-100 and HPC (1:2:2, w / w / w)

[0098] Fruquintinib (4 g) was added to a mixture of tetrahydrofuran, methanol and water (800 ml, 1 :4:0.2) at 60°C and stirred for 30 min to get clear solution. Eudragit L- 100 (8 g), HPC (8 g) and methanol (200 ml) were added to the above solution and then stirred for 15 min. The obtained solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0099] PXRD: Illustrated in Figure-6.

[0100] Glass Transition Temperature: 103.26 °C

[0101] Example-8a: Stability of amorphous solid dispersion of Fruquintinib with Eudragit L-100 and HPC (1:2:2, w / w)

[0102] The amorphous solid dispersion of Fruquintinib with Eudragit L-100 and HPC (1 :2:2, w / w), as prepared in example 8, was kept at 80% RH for one week in open condition and found to be physically and chemically stable.

[0103] Example-9: Process for the preparation of amorphous solid dispersion of Fruquintinib with HPC (1:4)

[0104] Fruquintinib (1 g) was added to a mixture of tetrahydrofuran, methanol and water (300 ml, 1 :4:0.2) at 60°C and stirred for 30 min to get clear solution. HPC (4 g) and methanol (100 ml) were added to the above solution and then stirred for 15 min. The obtained solution was filtered to make particle free. The obtained clear solution was spray dried to get the title compound.

[0105] PXRD: Illustrated in Figure-7.

[0106] Glass Transition Temperature: 62°C

[0107] Purity: 99.21% by HPLC

Claims

Claims:

1. An amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carriers.

2. The amorphous solid dispersion according to claim 1, wherein the pharmaceutically acceptable carrier is selected from a group of co-povidone, HPMC, HPMC-AS, HPC, Eudragit and mixture thereof.

3. The amorphous solid dispersion according to claim 1 to 2, wherein the ratio of Fruquintinib and pharmaceutically acceptable carrier is range from about 1:3 to about 1:10.

4. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is co-povidone.

5. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is hydroxy propyl methyl cellulose(HPMC).

6. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is hydroxy propyl methyl cellulose acetyl succinate (HPMC-AS).

7. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is hydroxy propyl cellulose (HPC).

8. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is Eudragit.

9. The amorphous solid dispersion of Fruquintinib of claim 1, wherein pharmaceutically acceptable carrier is a mixture of hydroxypropyl cellulose(HPC) and Eudragit.

10. The pharmaceutical composition comprising solid dispersion of claims 1 to 9 and one or more pharmaceutically acceptable excipients.

11. The use of amorphous solid dispersion of claim 1 for the treatment of metastatic colorectal cancer (mCRC).

Citation Information

Patent Citations

  • Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof

    US20190365738A1

  • Pharmaceutical preparation of fruquintinib and use thereof

    WO2020098795A1